News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
In response to growing demand for its biospecimens and research services, BioIVT has expanded its global commercial capabilities.
The company has appointed Alan Findlater to the newly-created role of chief commercial officer, a role in which he will be responsible for all of BioIVT’s commercial activities.
“With the rapid growth experienced by BioIVT, I look forward to bringing a unified approach to our commercial strategies,” Findlater told us. “Through cross-functional collaboration across our sales, marketing and client service teams, we will address competitive pressures by delivering a first-in-class customer experience through enhanced client relationships.”
Findlater was chief commercial officer at WIL Research Laboratories for more than five years before it was acquired by Charles River Laboratories in April 2016. He was then appointed as Charles Rivers’ executive director, global business development, safety assessment, discovery, and research models.
He also has held several senior global management positions at Covance Laboratories.